Eli Lilly stock surges 6% after Q2 earnings beat driven by Mounjaro, Zepbound

Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。